Galectin-3 Inhibitors project tests a small molecule, previously used in peripheral indications, for treating neuroinflammation in an Alzheimer’s mouse model. By blocking Galectin-3, it aims to reduce brain inflammation, with potential in other neurodegenerative diseases. The Galectin-3 Inhibitors project is testing the concept of treating neuroinflammation through a small molecule known to inhibit Galectin-3 in peripheral indications, via direct injection to the brain in the mouse model of Alzheimer’s disease. Galectin-3 is involved in neuroinflammation, thereby the project has a potential to be used in multiple neurodegenerative diseases. Galectin-3 inhibitors are a new class of drugs that could effectively treat neuroinflammation. Galectin-3 has shown to be a critical element in both peripheral as well as neuroinflammation. The project advances how inhibition leads to a resolution of brain inflammation.